Prevention of Acute Chemotherapy-induced Nausea and Vomiting: the Role of Palonosetron

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2010 Dec 29

PMID 21188127

Citations 1

Authors

Emilio Bajetta

Sara Pusceddu

Valentina Guadalupi

Monika Ducceschi

Luigi Celio

Affiliations

Soon will be listed here.

Abstract

Prevention of nausea and vomiting is the main goal of antiemetic treatment in cancer patients scheduled to receive chemotherapy. To prevent acute emesis, antiemetics should be administered just before chemotherapy and patients should be protected for up to 24 hours after chemotherapy initiation. The emetogenic potential of chemotherapeutic agents guides clinicians towards the most appropriate antiemetic prophylaxis. Current guidelines recommend the use of 5-HT(3) receptor antagonist (RA) either alone or in combination with dexamethasone and/or a neurokinin-1 RA both in the acute and delayed phases. The second-generation 5-HT(3)RA palonosetron exhibits a longer half-life and a higher binding affinity than older antagonists. Palonosetron has been approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients scheduled to receive either moderately (MEC) or highly emetogenic chemotherapy (HEC) and for the prevention of delayed CINV in patients receiving MEC. The present review will discuss the role of palonosetron in the prevention of acute CINV.

Citing Articles

Effect of Acupuncture on Delayed Emesis for the Patients Who Received High-Emetogenic Chemotherapy with Standard Antiemetic Prophylaxis (KHMC-HO-01): An Open-Label, Randomized Study.

Maeng C, Lee S, Han J, Kim H, Nam D, Lee J Evid Based Complement Alternat Med. 2022; 2022:9688727.

PMID: 35422869 PMC: 9005265. DOI: 10.1155/2022/9688727.

References

Lorusso V, Spedicato A, Petrucelli L, Saracino V, Giampaglia M, Perrone T . Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support Care Cancer. 2009; 17(12):1469-73. DOI: 10.1007/s00520-009-0611-9. View

Roila F, Donati D, Tamberi S, Margutti G . Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002; 10(2):88-95. DOI: 10.1007/s005200100295. View

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H . Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115-24. DOI: 10.1016/S1470-2045(08)70313-9. View

Kris M, Hesketh P, Somerfield M, Feyer P, Clark-Snow R, Koeller J . American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24(18):2932-47. DOI: 10.1200/JCO.2006.06.9591. View

Herrington J, Jaskiewicz A, Song J . Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 2008; 112(9):2080-7. DOI: 10.1002/cncr.23364. View

Navari R, Einhorn L, Loehrer Sr P, Passik S, Vinson J, McClean J . A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007; 15(11):1285. DOI: 10.1007/s00520-007-0248-5. View

Rojas C, Stathis M, Thomas A, Massuda E, Massuda E, Alt J . Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008; 107(2):469-78. DOI: 10.1213/ane.0b013e318172fa74. View

Thompson A, Lummis S . The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets. 2007; 11(4):527-40. PMC: 1994432. DOI: 10.1517/14728222.11.4.527. View

Griffin A, Butow P, Coates A, Childs A, Ellis P, Dunn S . On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7(2):189-95. DOI: 10.1093/oxfordjournals.annonc.a010548. View

10.

Coates A, Abraham S, Kaye S, Sowerbutts T, Frewin C, Fox R . On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983; 19(2):203-8. DOI: 10.1016/0277-5379(83)90418-2. View

11.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A . Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98(11):2473-82. DOI: 10.1002/cncr.11817. View

12.

Herrstedt J . Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2007; 5(1):32-43. DOI: 10.1038/ncponc1021. View

13.

Grunberg S, Koeller J . Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003; 4(12):2297-303. DOI: 10.1517/14656566.4.12.2297. View

14.

Geling O, Eichler H . Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005; 23(6):1289-94. DOI: 10.1200/JCO.2005.04.022. View

15.

Hietala J, Nyman M, Eskola O, Laakso A, Gronroos T, Oikonen V . Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain. Mol Imaging Biol. 2005; 7(4):262-72. DOI: 10.1007/s11307-005-7001-6. View

16.

Naeim A, Dy S, Lorenz K, Sanati H, Walling A, Asch S . Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol. 2008; 26(23):3903-10. DOI: 10.1200/JCO.2007.15.9533. View

17.

Einhorn L, Brames M, Dreicer R, Nichols C, Cullen Jr M, Bubalo J . Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer. 2007; 15(11):1293-1300. DOI: 10.1007/s00520-007-0255-6. View

18.

Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E . Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting. Tumori. 2008; 94(4):447-52. DOI: 10.1177/030089160809400401. View

19.

Hesketh P, Kris M, Grunberg S, Beck T, Hainsworth J, Harker G . Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15(1):103-9. DOI: 10.1200/JCO.1997.15.1.103. View

20.

Hesketh P . Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358(23):2482-94. DOI: 10.1056/NEJMra0706547. View